Incyte turns to Penn for a collaboration on next-gen cancer combos
Incyte has signed off on a multi-year deal to collaborate with scientists at the University of Pennsylvania on its next-gen combos and cancer therapies.
The university’s Abramson Cancer Center will take a lead role in looking at patient selection and combination opportunities as Incyte advances its plans to develop new and more effective immunotherapies. And they’ll be collaborating on a bioinformatics program in clinical immunotherapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.